The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug
Lipitor is one of the most commonly prescribed medicines on the planet, and one of the men behind it, Roger Newton, is currently working on a cheap and effective cholesterol-lowering drug.
In this segment from Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and contributor Todd Campbell talk about what we know about the drug's production so far, what it could mean for patients and the company if it's approved, how this treatment would be different and more accessible than both statins and PCSK9 inhibitors, and more.
A full transcript follows the video.
Source: Fool.com
Esperion Therapeutis.Inc. Aktie
1,72 €
4,51 %
Die Esperion Therapeutis.Inc. Aktie verzeichnet mehrere Buy-Einschätzungen, was auf eine positive Tendenz hindeutet.
Ein Kursziel von 9 € für Esperion Therapeutis.Inc. würde den aktuellen Kurs von 1.72 € signifikant übertreffen.
